ReviewGenes2022
Chimeric RNAs Discovered by RNA Sequencing and Their Roles in Cancer and Rare Genetic Diseases.
Review in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- MYCN and helicases DDX17 and DDX5 have opposite effects on the production of readthrough-associated chimeric transcripts.Cellular and molecular life sciences : CMLS · 2026Article
- Novel Perspectives onEpigenomes · 2026Article
- Induction of ferroptosis in prostate cancer by CCDC7Cell death and differentiation · 2026Article
- Identification of ATP9A-NFATC2 gene fusion transcript in Behcet's disease, a subtype of uveitis.Indian journal of ophthalmology · 2026Article
- Cross-Species Insights Into Gamma Herpesvirus Transcriptomes: Long-Read and Multi-Omics Perspectives.Journal of medical virology · 2026Review
- ABRAXAS1-HELQ is a candidate class-matched reference chimeric RNA and contributes to prostate cell motility through MCOLN2.Frontiers in oncology · 2026Article
- Antisense Oligonucleotide-Mediated Chimeric RNA Knockdown.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Chimeric RNA isoforms generated by diverse mechanisms from two C-type lectins modulate innate immunity in arthropods.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Revealing the role of U2AF1 in splicing regulation and chimeric RNA dynamics.Scientific reports · 2025Article
- Chimeric mitochondrial RNA transcripts predict mitochondrial genome deletion mutations in mitochondrial genetic diseases and aging.Genome research · 2025Article
- Direct RNA sequencing in plants: Practical applications and future perspectives.Plant communications · 2024Review
- Conserved features and diversity attributes of chimeric RNAs across accessions in four plants.Plant biotechnology journal · 2024Article
- OncogenicMedComm · 2024Article
- Effective requesting method to detect fusion transcripts in chronic myelomonocytic leukemia RNA-seq.NAR genomics and bioinformatics · 2024Article
- Detection of novel PPP1R1B::STARD3 fusion transcript in acute myeloid leukemia: a case report.Journal of medical case reports · 2024Article
- MALAT1 functions as a transcriptional promoter of MALAT1::GLI1 fusion for truncated GLI1 protein expression in cancer.BMC cancer · 2023Article
- The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients.Viruses · 2023Article
- Recent advances in cancer fusion transcript detection.Briefings in bioinformatics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric RNAs are transcripts that are generated by gene fusion and intergenic splicing events, thus comprising nucleotide sequences from different parental genes. In the past, Northern blot analysis and RT-PCR were used to detect chimeric RNAs. However, they are low-throughput and can be time-consuming, labor-intensive, and cost-prohibitive. With the development of RNA-seq and transcriptome analyses over the past decade, the number of chimeric RNAs in cancer as well as in rare inherited diseases has dramatically increased. Chimeric RNAs may be potential diagnostic biomarkers when they are specifically expressed in cancerous cells and/or tissues. Some chimeric RNAs can also play a role in cell proliferation and cancer development, acting as tools for cancer prognosis, and revealing new insights into the cell origin of tumors. Due to their abilities to characterize a whole transcriptome with a high sequencing depth and intergenically identify spliced chimeric RNAs produced with the absence of chromosomal rearrangement, RNA sequencing has not only enhanced our ability to diagnose genetic diseases, but also provided us with a deeper understanding of these diseases. Here, we reviewed the mechanisms of chimeric RNA formation and the utility of RNA sequencing for discovering chimeric RNAs in several types of cancer and rare inherited diseases. We also discussed the diagnostic, prognostic, and therapeutic values of chimeric RNAs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.